Quadruple therapy with furazolidone for retreatment in patients with peptic ulcer disease

World Journal of Gastroenterology

Volumn 14, Issue 40, 2008, Pages 6224-6227

  Felga, Guilherme Eduardo Gonçalves ^a   Silva, Fernando Marcuz ^a   Barbuti, Ricardo Correa ^a   Navarro Rodriguez, Tomás ^a   Zaterka, Schlioma ^a   Eisig, Jaime Natan ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Duodenal ulcer; Furazolidone; Gastric ulcer; Helicobacter pylori; Retreatment

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; FURAZOLIDONE; OMEPRAZOLE; ANTIINFECTIVE AGENT; ANTIULCER AGENT; ORGANOMETALLIC COMPOUND; PROTON PUMP INHIBITOR;

ADULT; ARTICLE; COHORT ANALYSIS; DIARRHEA; DISEASE ASSOCIATION; DIZZINESS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; ERADICATION THERAPY; FEMALE; HELICOBACTER INFECTION; HUMAN; MAJOR CLINICAL STUDY; MALE; NAUSEA; PEPTIC ULCER; RETREATMENT; TREATMENT FAILURE; UNSPECIFIED SIDE EFFECT; AGED; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG COMBINATION; DRUG EFFECT; HELICOBACTER PYLORI; MICROBIOLOGY; MIDDLE AGED; RECURRENT DISEASE; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; AMOXICILLIN; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FURAZOLIDONE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; OMEPRAZOLE; ORGANOMETALLIC COMPOUNDS; PEPTIC ULCER; PROTON PUMP INHIBITORS; RECURRENCE; SALVAGE THERAPY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 61949223952     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.6224     Document Type: Article

References (34)

1. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-1315
2. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
3. Gisbert JP, Pajares JM. Review article: Helicobacter pylori infection and gastric outlet obstruction - prevalence of the infection and role of antimicrobial treatment. Aliment Pharmacol Ther 2002; 16: 1203-1208
4. Parente F, Cucino C, Bianchi Porro G. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003; 35: 523-528
5. Graham DY, Lew GM, Malaty HM, Evans DG, Evans DJ Jr, Klein PD, Alpert LC, Genta RM. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-496
6. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-1055
7. Mendonca S, Ecclissato C, Sartori MS, Godoy AP, Guerzoni RA, Degger M, Pedrazzoli J Jr. Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxicillin, tetracycline, and furazolidone in Brazil. Helicobacter 2000; 5: 79-83
8. White AH. Absorption, distribution, metabolism, and excretion of furazolidone. A review of the literature. Scand J Gastroenterol Suppl 1989; 169: 4-10
9. Fakheri H, Merat S, Hosseini V, Malekzadeh R. Lowdose furazolidone in triple and quadruple regimens for Helicobacter pylori eradication. Aliment Pharmacol Ther 2004; 19: 89-93
10. Altamirano A, Bondani A. Adverse reactions to furazolidone and other drugs. A comparative review. Scand J Gastroenterol Suppl 1989; 169: 70-80
11. Queiroz DM, Coimbra RS, Mendes EN, Rocha GA, Alves VM, Oliveira CA, Lima Junior GF. Metronidazole-resistant Helicobacter pylori in a developing country. Am J Gastroenterol 1993; 88: 322-323
12. Zaterka S, Eisig JN, Chinzon D, Rothstein W. Factors related to Helicobacter pylori prevalence in an adult population in Brazil. Helicobacter 2007; 12: 82-88
13. Eisig JN, Andre SB, Silva FM, Hashimoto C, Moraes-Filho JP, Laudanna AA. The impact of Helicobacter pylori resistance on the efficacy of a short course pantoprazole based triple therapy. Arq Gastroenterol 2003; 40: 55-60
14. Xia HH, Talley NJ, Kam EP, Young LJ, Hammer J, Horowitz M. Helicobacter pylori infection is not associated with diabetes mellitus, nor with upper gastrointestinal symptoms in diabetes mellitus. Am J Gastroenterol 2001; 96: 1039-1046
15. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004; 64: 1893-1904
16. Silva FM, Zaterka S, Eisig JN, Chehter EZ, Chinzon D, Laudanna AA. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med Sao Paulo 2001; 56: 11-16
17. Queiroz DM, Dani R, Silva LD, Santos A, Moreira LS, Rocha GA, Correa PR, Reis LF, Nogueira AM, Alvares Cabral MM, Esteves AM, Tanure J. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002; 35: 315-320
18. Godoy AP, Ribeiro ML, Benvengo YH, Vitiello L, Miranda Mde C, Mendonca S, Pedrazzoli J Jr. Analysis of antimicrobial susceptibility and virulence factors in Helicobacter pylori clinical isolates. BMC Gastroenterol 2003; 3: 20
19. Zaterka S, Eisig JN, Chinzon D, Boyd HK, Bastos A, Dias T, Laudanna AA. Five day and ten day triple therapy (amoxicillin, furazolidone and metronidazole) in the treatment of duodenal ulcer. Rev Hosp Clin Fac Med Sao Paulo 1996; 51: 162-165
20. Kwon DH, Lee M, Kim JJ, Kim JG, El-Zaatari FA, Osato MS, Graham DY. Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance. Antimicrob Agents Chemother 2001; 45: 306-308
21. Osato MS, Reddy R, Reddy SG, Penland RL, Malaty HM, Graham DY. Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. Arch Intern Med 2001; 161: 1217-1220
22. Malekzadeh R, Merat S, Derakhshan MH, Siavoshi F, Yazdanbod A, Mikaeli J, Sotoudemanesh R, Sotoudeh M, Farahvash MJ, Nasseri-Moghaddam S, Pourshams A, Dolatshahi S, Abedi B, Babaei M, Arshi S, Majidpour A. Low Helicobacter pylori eradication rates with 4- and 7-day regimens in an Iranian population. J Gastroenterol Hepatol 2003; 18: 13-17
23. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-1001
24. Fakheri H, Malekzadeh R, Merat S, Khatibian M, Fazel A, Alizadeh BZ, Massarrat S. Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate. Aliment Pharmacol Ther 2001; 15: 411-416
25. Isakov V, Domareva I, Koudryavtseva L, Maev I, Ganskaya Z. Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. Aliment Pharmacol Ther 2002; 16: 1277-1282
26. Eisig JN, Silva FM, Rodriguez TN, Hashimoto CL, Barbuti RC. A furazolidone-based quadruple therapy for Helicobacter pylori retreatment in patients with peptic ulcer disease. Clinics 2005; 60: 485-488
27. Segura AM, Gutierrez O, Otero W, Angel A, Genta RM, Graham DY. Furazolidone, amoxycillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 529-532
28. Roghani HS, Massarrat S, Shirekhoda M, Butorab Z. Effect of different doses of furazolidone with amoxicillin and omeprazole on eradication of Helicobacter pylori. J Gastroenterol Hepatol 2003; 18: 778-782
29. Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of Helicobacter pylori infection. Dig Dis 2006; 24: 113-130
30. Ebrahimi-Dariani N, Mirmomen S, Mansour-Ghanaei F, Noormohammadpoor P, Sotodehmanesh R, Haghpanah B, Bahrami H. The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. Med Sci Monit 2003; 9: PI105-PI108
31. Malekzadeh R, Ansari R, Vahedi H, Siavoshi F, Alizadeh BZ, Eshraghian MR, Vakili A, Saghari M, Massarrat S. Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease. Aliment Pharmacol Ther 2000; 14: 299-303
32. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, El-Zimaity HM. Furazolidone combination therapies for Helicobacter pylori infection in the United States. Aliment Pharmacol Ther 2000; 14: 211-215
33. Qasim A, Sebastian S, Thornton O, Dobson M, McLoughlin R, Buckley M, O'Connor H, O'Morain C. Rifabutin- and furazolidone-based Helicobacter pylori eradication therapies after failure of standard first- and second-line eradication attempts in dyspepsia patients. Aliment Pharmacol Ther 2005; 21: 91-96
34. Wong WM, Wong BC, Lu H, Gu Q, Yin Y, Wang WH, Fung FM, Lai KC, Xia HH, Xiao SD, Lam SK. One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies. Aliment Pharmacol Ther 2002; 16: 793-798